Toggle navigation
TWunroll
TWunroll
faq
Contact US
Hilda Bastian, PhD
hildabast
Preprint of the South African phase 1b/2 trial for the Oxford/AstraZeneca vaccine is online. Primary efficacy analysis is for 2,026 people who weren't infected with HIV (there was also a
Read more
Another Covid vaccine to go into phase 2/3 trial in Asia, Latin America, US. It's UB-612, peptide-based vaccine that's hoped to help prevent infection. https://clinicaltrials.gov/ct2/show/NCT04683224 Deal to produce for India
Read more
New data for the Oxford/AstraZeneca vaccine, with extra month's worth of data, & combining 4 trials from phase 1 to 3, focusing on 1st dose: Indian phase 2/3 trial still
Read more
Phase 3 trial for Sputnik V results landed!To keep in mind: randomized 3 to 1 (not half in vax group, half placebo). It's a pair of vaccines, 1 shot of
Read more
It's on the agenda this week: possibly a decision on the Oxford/AstraZeneca vaccine from EMA's (Euro drug regulator) Human Medicine Committee? Applicants will be questioned at the meeting.(EMA process steps
Read more
Large phase 2 trial of Novavax vaccine in South Africa reportedly has data, reporting soon. Minimum of 3,000 people (up to 4,400), mostly HIV-neg but with 240-person HIV-positive group. Biggest
Read more
Press conference on results of Brazilian trial of CoronaVac, Sinovac's inactivated vaccine, cleared up the efficacy data & made the complexity of comparing a trial in healthcare professionals with others
Read more
Confirmation on the 78% for mild Covid-19 subgroup for Sinovac's inactivated vaccine CoronaVac: excluded people who didn't need medical care. Overall efficacy likely in the low 60s https://archive.vn/Ms4nM Depending on
Read more
MHRA's (UK drug regulator) 57-page Public Assessment Report on Oxford/AstraZeneca vax is out: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/949772/UKPAR_COVID_19_Vaccine_AstraZeneca_05.0
Read more
Statement from the UK Joint Committee on Vaccination & Immunisation (JCVI) on why they believe their strategy will achieve maximum impact: https://app.box.com/s/uwwn2dv4o2d0ena726gf4403f3p2acnu 1/n ...They point out that most of the
Read more
Well, dear readers, my take on "the winning formula" for Oxford/AstraZeneca did not age well. According to the Indian manufacturing partner, it isn't the "low"-dose-1st subgroup. It's another subgroup, perhaps
Read more
MHRA verdict reportedly coming any day for the Oxford/AstraZeneca vaccine. I've been asked if I think their process is comparable to FDA's. Good question, post-Brexit. So I looked at 3
Read more
‹
1
2
›
By continuing to use the site, you are consenting to the use of cookies as explained in our
Cookie Policy
to improve your experience.
I agree